Earnings History Data for 9 Meters Biopharma, Inc. (NMTR) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
9 Meters Biopharma, Inc.
9 Meters Biopharma, Inc. is a rare, orphan and unmet needs focused GI company. It's advancing NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for Short Bowel Syndrome, a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom. 9 Meters Biopharma Inc., formerly known as Innovate Bioph, is based in Raleigh, United States.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28-03-2023 | PM | NMTR | 9 Meters Biopharma | 17.00 | -0.92 | -0.80 | 0.00 | 9 Meters Biopharma GAAP EPS of -$0.92 misses by $0.12 [3/28/2023 8:52 AM] |
1.35 | 0.01 (1.12%) |
0.0 | 0.0 (0.00%) |
1.00 - 13.20 | 52,212 | 80,000 | 0 | ||
| 08-11-2022 | PM | NMTR | 9 Meters Biopharma | 28.00 | -0.72 | -0.83 | 0.00 | 9 Meters Biopharma GAAP EPS of -$0.72 beats by $0.10 [11/8/2022 8:53 AM] |
2.19 | -0.05 (-2.23%) |
2.20 | -0.04 (-1.79%) |
2.11 - 24.80 | 70,407 | 70,000 | 733 | ||
| 15-08-2022 | PM | NMTR | 9 Meters Biopharma | 68.00 | -0.04 | -0.04 | 0.00 | 9 Meters Biopharma GAAP EPS of -$0.04 in-line [8/15/2022 7:53 AM] |
3.76 | -0.21 (-5.29%) |
0.26 | -0.01 (-2.60%) |
3.68 - 12.42 | 14,481 | 20,000 | 66,475 | ||
| 16-05-2022 | PM | NMTR | 9 Meters Biopharma | 98.00 | -0.04 | -0.04 | 0.00 | 9 Meters Biopharma GAAP EPS of -$0.04 [5/16/2022 7:57 AM] |
0.4105 | 0.03 (9.03%) |
0.39 | 0.01 (3.59%) |
0.35 - 1.55 | 2,518,238 | 1,250,000 | 10,276 | ||
| 23-03-2022 | PM | NMTR | 9 Meters Biopharma | 149.00 | -0.04 | -0.04 | 0.00 | 9 Meters Biopharma Non-GAAP EPS of -$0.04 [3/23/2022 9:14 AM] |
0.5650 | -0.03 (-4.51%) |
0.6068 | 0.02 (2.55%) |
0.51 - 1.55 | 1,158,925 | 1,423,570 | 13,456 | ||
| 22-03-2021 | AH | NMTR | 9 Meters Biopharma, Inc. | 335.61 | N/A | -0.04 | 0.00 | 9 Meters Biopharma reports Q4 results [3/22/2021 4:05 PM] |
1.50 | -0.25 (-14.49%) |
1.57 | -0.19 (-10.80%) |
0.38 - 2.26 | 9,417,334 | 4,410,000 | 338,504 | ||